Results 241 to 250 of about 88,988 (279)

Long-term outcomes of intravitreal 0.19 mg fluocinolone acetonide implant in uveitic macular edema after prior local corticosteroid treatments. [PDF]

J Ophthalmic Inflamm Infect
Ferreira AM, Silva MI, Torres-Costa S, Oliveira-Ferreira C, Pedrosa AC, Figueira L, Araújo JR.   +6 more
europepmc   +1 more source

Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges

, 2019
Horace Massa, Pipis SY, T. Adewoyin, Athanasios Vergados, Sudeshna Patra, Panos GD   +5 more
openalex   +1 more source

DME-RWKV: An Interpretable Multimodal Deep Learning Framework for Predicting Anti-VEGF Response in Diabetic Macular Edema. [PDF]

Bioengineering (Basel)
Liu Y, Xu X, Zhang J, Wang H, Shen A, Song X, Xu X, Fu Y.   +7 more
europepmc   +1 more source

Efficacy of dexamethasone intravitreal implant combined with anti-VEGF drugs in the treatment of diabetic macular edema: a systematic review and meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Chen F, Wang X, Chen M, Xin M, Xian Y.
europepmc   +1 more source

AI-Assisted OCT Clinical Phenotypes of Diabetic Macular Edema: A Large Cohort Clustering Study. [PDF]

J Clin Med
Midena E, Lupidi M, Toto L, Covello G, Veritti D, Pilotto E, Cicinelli MV, Lattanzio R, Figus M, Midena G, Danieli L, Borrelli E, Reibaldi M, Tognetto D, Inferrera L, Donati S, Rossi S, Melillo P, Lanzetta P, Sarao V, Gregori G, Cagini C, Eandi CM, Carnevali A, Scorcia V, Maggio E, Pertile G, Costagliola C, Cennamo G, Mora P, Dell'Omo R, Affatato M, Passamonti M, Parravano M, Lassandro NV, Nassisi M, Viola F, Castellino N, Cappellani F, Giannaccare G, Boscia F, Grassi MO, Musetti D, Folegani V, Invernizzi A, Rossetti L, Bacci T, Ricci F, Lombardo M, Romano M, Valsecchi N, Coppola M, Cavarzeran F, Frizziero L.   +53 more
europepmc   +1 more source

Comparative efficacy of intravitreal aflibercept biosimilar QL1207 versus reference aflibercept in the treatment of diabetic macular edema. [PDF]

Front Med (Lausanne)
Zhai G, Liu N, Wang S, Zhang X.
europepmc   +1 more source

Three-year outcomes of cystotomy for cystoid macular edema secondary to retinal vein occlusion. [PDF]

PLoS One
Sotani Y, Imai H, Yamada H, Miki A, Nakamura M.   +4 more
europepmc   +1 more source

Impact of Vision Impairment and Microperimetry Parameters on Quality of Life in Patients with Center-Involving Diabetic Macular Edema. [PDF]

Ophthalmol Sci
Piccoli G, Fenwick EK, Bucceri V, Lamoureux EL, Tagliabue E, Nucci P, Vujosevic S.   +6 more
europepmc   +1 more source

Real-World Functional and Anatomic Outcomes With Aflibercept 8.0 mg in Patients With Diabetic Macular Edema. [PDF]

J Vitreoretin Dis
Barbosa GCS, Bala S, Mohan N, Srivastava SK, Kaiser PK, Sastry A, Babiuch AS, Sears J, Talcott KE, Yuan A, Rachitskaya A, Ehlers JP, Schachat AP, Lin P, Sharma S, Mammo DA.   +15 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Diabetic macular edema

Disease-a-Month, 2021
Diabetic retinopathy (DR) is a leading cause of preventable blindness world-wide. Diabetic macular edema (DME) is the most common cause of moderate vision loss in patients with diabetes. Although treatments for DME have improved significantly over the past decades, the burden of this disease remains high for patients and the healthcare system alike ...
Melissa, Ixcamey, Camille, Palma
openaire   +2 more sources